Literature DB >> 32731230

A Comprehensive Update on Intestinal- and Non-Intestinal-Type Adenocarcinomas.

Vincent Vander Poorten1,2, Mark Jorissen3,4.   

Abstract

This review of sinonasal adenocarcinoma, both intestinal and non-intestinal type, aims at providing a comprehensive overview of etiological factors, diagnostic workup, histological subtypes, advances in molecular characterization and the genetic basis, current optimal treatment strategies, resulting oncological outcome, and prognostic factors modifying the final treatment results. The current treatment of choice remains surgical resection with a curative intent, using the least invasive approach that allows for removal of the entire tumor with negative margins, supplemented with postoperative high-quality intensity-modulated radiotherapy in the majority of patients. To date, chemotherapy remains reserved for the palliative setting. The progress in understanding the underlying molecular biological mechanisms has not yet translated into standard of care applications.
© 2020 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2020        PMID: 32731230     DOI: 10.1159/000457934

Source DB:  PubMed          Journal:  Adv Otorhinolaryngol        ISSN: 0065-3071


  2 in total

1.  Case Report: Response to Intra-arterial Cisplatin and Concurrent Radiotherapy Followed by Salvage Surgery in a Patient With Advanced Primary Sinonasal Low-Grade Non-intestinal Adenocarcinoma.

Authors:  Hirohiko Tachino; Hiromasa Takakura; Hideo Shojaku; Michiro Fujisaka; Katsuichi Akaogi; Hideto Kawabe; Norihito Naruto; Hiroko Shojaku; Kyo Noguchi; Shigeharu Miwa; Johji Imura; Yoshinobu Maeda
Journal:  Front Surg       Date:  2020-12-10

Review 2.  Malignant Sinonasal Tumors: Update on Histological and Clinical Management.

Authors:  Alessandra Bracigliano; Fabiana Tatangelo; Francesco Perri; Giuseppe Di Lorenzo; Roberto Tafuto; Alessandro Ottaiano; Ottavia Clemente; Maria Luisa Barretta; Nunzia Simona Losito; Mariachiara Santorsola; Salvatore Tafuto
Journal:  Curr Oncol       Date:  2021-07-01       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.